SGIOY:OTCMKTS
Shionogi 2 ADR Representing 1 Ord Shs
$8,81
arrow_upward
+1,50%(+0,13) 1G
13 Eki, 16:00:00 GMT-4 · USD
search
Tüm semboller
| Sembol | Fiyat | DeÄŸiÅŸiklik | DeÄŸiÅŸiklik % |
|---|
insights_autoSGIOY ile ilgili en önemli analizler oluşturuluyor...
Açık
$8,66
Yüksek
$8,85
Düşük
$8,66
Piy. deÄŸ.
2,50Â Tn
Ort. hacim
169,23Â B
Ä°ÅŸlem Hacmi
118,89Â B
52 haftalık en yüksek
$12,00
52 haftalık en düşük
$7,65
Beta
0,07
Tedavüldeki hisse senedi sayısı
1,78Â Mr
Çalışan sayısı
6Â B
Açık
$8,66
Yüksek
$8,85
Düşük
$8,66
Piy. deÄŸ.
2,50Â Tn
Ort. hacim
169,23Â B
Ä°ÅŸlem Hacmi
118,89Â B
52 haftalık en yüksek
$12,00
52 haftalık en düşük
$7,65
Beta
0,07
Tedavüldeki hisse senedi sayısı
1,78Â Mr
Çalışan sayısı
6Â B
Haberler
Web kaynaklarından ve haber iş ortaklarından
GlobeNewswire
·
15 dakika önce
FBS Global Regains Compliance with Nasdaq Minimum Bid Price Requirement
Stock Titan
·
20 dakika önce
After 30 business days below $1, AGM Group (Nasdaq: AGMH) gets time to regain compliance.
Seeking Alpha
·
36 dakika önce
Three things to look out for on Wednesday
Investor's Business Daily
·
11 dakika önce
Dow Jones Futures: Stock Market Holds Up As Meta, AMD Lead Buys; ASML, CPI Inflation Due
Profil
Shionogi & Company, Limited is a Japanese pharmaceutical company best known for developing Crestor. Medical supply and brand name also uses katakana.
Shionogi has business roots that date back to 1878, and was incorporated in 1919. Among the medicines produced are for hyperlipidaemia, antibiotics, and cancer medicines.
In Japan it is particularly known as a producer of antimicrobial and antibiotics. Because of antibiotic resistance and slow growth of the antibiotic market, it has teamed up with US based Schering-Plough to become a sole marketing agent for its products in Japan.
Shionogi had supported the initial formation of Ranbaxy Pharmaceuticals, a generic manufacturer based in India. In 2012 the company became a partial owner of ViiV Healthcare, a pharmaceutical company specialising in the development of therapies for HIV.
The company is listed on the Tokyo Stock Exchange and Osaka Securities Exchange and is constituent of the Nikkei 225 stock index.
In June 2023, Shionogi announced its acquisition of Qpex Biopharma for approximately $140m.
On 5 October 2026, Shionogi announced an agreement to acquire IntraBio for US$2 billion through its US subsidiary, Shionogi Inc. Wikipedia
Shionogi 2 ADR Representing 1 Ord Shs hakkında
CEOIsao Teshirogi
Çalışan Sayısı6,22 B
KuruluÅŸ Tarihi1878
Genel Merkez-
Sektör-
Web Sitesishionogi.com